Investor presentation

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

Investor presentation

London, UK, 30 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that Tim Watts, Chief Executive Officer, will present at the Proactive One2One Virtual Investor Forum on Thursday 8 April 2021.

Shield will be one of three companies presenting on the evening, each having a presentation slot followed by Q&A, with the webinar taking place from 6.00pm. Investors can register to attend here:

https://event.webinarjam.com/register/1024/gwwg2hxq9

No new material information will be disclosed at the event and the presentation will be made available on the Company's website shortly after the event here:  https://www.shieldtherapeutics.com/investors/presentations  

For further information, please contact:

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx